Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symtri study: TAF/FTC/DRV/cobi vs ABC/3TC/DTG in treatment-naive HIV infection
2018-001645-14Phase 4Active
- Sponsor
- Spanish HIV/AIDS Research Networkº
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing TAF/FTC/DRV/cobi regimen with ABC/3TC/DTG regimen (2 arms). Primary endpoint: Virologic suppression at Week 48. Started Jun 2018; status: active.
02
Drugs
darunavircobicistatemtricitabinetenofovir alafenamidedolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-001645-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001645-14.